In health economic evaluations utilities are a key component of Quality Adjusted life Years (QALYs). Utility is rated on a scale of 0-1 and represents patients or societal preferences for different health states. QALYs are globally relevant but have particular important for pricing, reimbursement and market access decisions in a number of key countries including the UK (where they are a requirement for NICE and SMC submissions), Australia, Canada, Sweden. Pressures to produce robust utility
estimates to show the benefits of new pharmaceuticals and health technologies are increasing. There are several methods for generating utilities, including the use of generic utility instruments such as the EQ 5D, SF-6D or HUI in clinical trials, mapping from a disease specific quality of life questionnaire to a generic utility instrument or direct measurement using time trade-off or standard gamble, completed in members of the public or patients. Ideally, the choice of approaches should be carefully considered well
before drug launch and a international utility strategy developed alongside phase III clinical trials.
Mapi Values has experience in performing a range of utility studies including both direct measurement and mapping (to EQ 5D) studies. We benefit from the Adelphi partnership for the rapid conduct of time trade-off interviews and expertise in Patient-Reported Outcomes (PROs) to ensure high quality direct measurement utility studies are performed.